IPR and Global Health: The Challenge of Knowledge-Sharing

IPR and Global Health: The Challenge of Knowledge-Sharing

Discussions of sharing knowledge for global health initiatives typically conjure images of children afflicted with neglected tropical diseases. Knowledge sharing seems like an important but comfortably distant concern for those in industrialized countries. In fact, far from being localized to diseases endemic to developing countries, the concerns -- and challenges -- of sharing health knowledge are truly global.

Take genomic science, a field with deep relevance to residents of industrialized countries, to whom it promises a future of increasingly personalized medicine. Yet that future of tailored therapy depends on the ability to access the collective building blocks of the human genome. Scientists involved in the publicly funded Human Genome Project understood that need. Therefore, leading genome-sequencing centers funded by the Wellcome Trust and the U.S. National Institutes of Health (NIH) committed to depositing gene sequences -- every 1,000 base pairs -- into a publicly available database, the GenBank, within 24 hours of completing their work. These cross-national norms, called the Bermuda Rules, were intended to prevent the patenting of DNA sequences through defensive publishing. Moreover, consequences were attached to a failure to follow the rules: The NIH suggested that the patenting of work emerging from the publicly funded Human Genome Project would count against one’s likelihood of receiving subsequent funding.

And yet, these funder norms have done little to stem the patenting of genes. To take one example, in Europe and North America, the firm Myriad Genetics is at the center of a fight over the patenting of genes related to the diagnosis of breast and ovarian cancer. Myriad has fought to limit alternative tests of the genetic markers for which it claims patents and has positioned itself to control certain genetic data for breast and ovarian cancer. Arguing that Myriad’s patents “undermine the free exchange of information and scientific freedom,” the American Civil Liberties Union and the Public Patent Foundation at the Benjamin N. Cardozo School of Law have challenged the patent claims over these “products of nature” in U.S. courts.

Keep reading for free!

Get instant access to the rest of this article by submitting your email address below. You'll also get access to three articles of your choice each month and our free newsletter:

Or, Subscribe now to get full access.

Already a subscriber? Log in here .

What you’ll get with an All-Access subscription to World Politics Review:

A WPR subscription is like no other resource — it’s like having a personal curator and expert analyst of global affairs news. Subscribe now, and you’ll get:

  • Immediate and instant access to the full searchable library of tens of thousands of articles.
  • Daily articles with original analysis, written by leading topic experts, delivered to you every weekday.
  • Regular in-depth articles with deep dives into important issues and countries.
  • The Daily Review email, with our take on the day’s most important news, the latest WPR analysis, what’s on our radar, and more.
  • The Weekly Review email, with quick summaries of the week’s most important coverage, and what’s to come.
  • Completely ad-free reading.

And all of this is available to you when you subscribe today.

More World Politics Review